...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Cellular Physiology >Galectin-3 expression in thyroid fine needle cytology (t-FNAC) uncertain cases: Validation of molecular markers and technology innovation
【24h】

Galectin-3 expression in thyroid fine needle cytology (t-FNAC) uncertain cases: Validation of molecular markers and technology innovation

机译：Galectin-3表达在甲状腺细针细胞学(t-FNAC)不确定的情况下:验证的分子标记和技术创新

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Thyroid cancer is not very common, accounting for 1-2% of all cancers, with a population incidence of about 0.004%. Currently, the ability to discriminate between follicular adenoma and carcinoma represents the major challenge in preclinical diagnosis of thyroid proliferative lesions. Better discrimination between the two would help avoid unnecessary thyroidectomy and save valuable resources. Over the years, galectin-3 (Gal-3) has been proposed as a diagnostic marker with varied success. In this paper, we used Environmental Scanning Electron Microscopy Immunogold Labelling (ESEM-IGL) to investigate the expression of Gal-3 on Thin-Prep fine needle aspiration cytology (FNAC). We optimized the ESEM-IGL method on thyroid cell lines (RO-82 and FTC-133) comparing our membrane Gal-3 labeling data with Western blot. We evaluated 183 thyroid FNAC from Italian patients with a uncertain pre-surgical diagnosis. ESEM-IGL method marker sensitivity is 71.2%, while specificity is 53.3% and diagnostic efficacy is 61.2%. Our results confirmed that Gal-3 expression is associated with situations of hypertrophy and/or cellular hyperproliferation, pathophysiological situations common both to adenomas and to thyroid carcinomas. The innovation of thyroid FNAC Thin-Prep ESEM-IGL shows the levels of Gal-3 immunolabeling clearly, even through the individual cells of a thyroid nodule. However, Gal-3 alone, as a molecular marker of thyroid cancer, can still have a limited application in pre-surgery diagnosis. J. Cell. Physiol. ? 2012 Wiley Periodicals, Inc.
机译：甲状腺癌并不常见,占1 - 2%的癌症人口发病率约为0.004%。区分和滤泡性腺瘤癌代表的重大挑战临床诊断甲状腺增生性病变。将有助于避免不必要的甲状腺切除术和节省宝贵的资源。galectin-3 (Gal-3)已经被提议作为诊断标记不同的成功。论文中,我们使用环境扫描电子标签(ESEM-IGL)然后显微电镜下观察调查Thin-Prep Gal-3的表达良好的针吸细胞学(FNAC)。优化ESEM-IGL方法甲状腺细胞行(ro - 82和ftc - 133)比较我们的膜与免疫印迹Gal-3标签数据。评估183年甲状腺FNAC从意大利病人不确定的术前诊断。标记方法的敏感性是71.2%,特异性为53.3%,诊断效果61.2%。表达情况肥大和/或细胞增生,常见的两个病理生理情况腺瘤及甲状腺癌。创新的甲状腺FNAC Thin-Prep ESEM-IGL显示的水平Gal-3 immunolabeling很明显,甚至通过甲状腺的单个细胞结节。甲状腺癌的标志,仍然可以有一个限制在术前诊断中的应用。细胞。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号